ASCO Connection

July 2017

Issue link: http://read.uberflip.com/i/845028

Contents of this Issue

Navigation

Page 1 of 67

TARGET PD-L1 BLOCKADE Indication IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verifi cation and description of clinical benefi t in confi rmatory trials.

Articles in this issue

Archives of this issue

view archives of ASCO Connection - July 2017